KCCure Launches National Kidney Cancer Patient Advisory Board

WASHINGTON – The Kidney Cancer Research Alliance (KCCure) announced today the formation of a national kidney cancer Patient Advisory Board; a non-voting body made up of patients, caregivers and leaders in the cancer community.  The board will be led by patient advocates Michael B. Lawing and Debra Gottsleben.  Members will provide guidance to KCCure’s research agenda, assist in developing patient education materials, enhance and expand outreach to other patients, and participate as reviewers in KCCure’s research grant process. “Patient expertise is an untapped resource when it comes to kidney cancer,” said KCCure President, Dena Battle.  “This board is an invaluable part of our effort to effectively tailor research priorities based on the needs of all kidney cancer patients. I’m grateful t...

KCCure President Dena Battle Elected to National Cancer Institute’s Renal Task Force

WASHINGTON - Kidney Cancer Research Alliance (KCCure) President Dena Battle has been elected to the National Cancer Institute’s Renal Task Force to serve as one of two patient advocates on the panel. 

New first line standard of care treatment for Stage 4 RCC

New data from the pivotal phase 3 Checkmate 214 trial combining ipilumimab and nivolumab presented at the European Society of Medical Oncology (ESMO) conference in Madrid showed superiority for the combination over Sunitinib (Sutent). The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was more effective in prolonging the lives of newly diagnosed metastatic renal cell carcinoma patients than the current standard of care, sunitinib (Sutent), showing the highest complete response rate (9 percent) ever seen in a phase 3 trial for RCC. As a result of the positive data, the trial’s Independent Data Monitoring Committee ended the trial prematurely signaling that the combination will likely move forward for approval as a first line treatment in patients with metastatic RCC. What does th...

KCCure Awards Inaugural Grant of $100,000 to Dana Farber for work in CAR T-Cell Research

WASHINGTON – The Kidney Cancer Research Alliance (KCCure) announced today that their first research grant of $100,000 has been awarded to Dr. Wayne Marasco, at Dana Farber Cancer Center for his proposal: CAR T-Cell Factories that change the Tumor Microenvironment to Achieve RCC Cures. “I am incredibly grateful to receive this award.  These funds will help support our translational program to bring CAR T cell therapy into the clinic. We are totally aligned with KCCure’s mission to find a kidney cancer cure,” said Dr. Marasco. “This is a milestone for KCCure and for kidney cancer research as a whole,” said Dr. Hans Hammers, cofounder and head of the scientific advisory board for KCCure.  “CAR T-Cell research is emerging as one of the most exciting new areas in cancer treatment and we b...

Show your colors for World Kidney Cancer Day by helping us fund more research!

Are we green or orange?? That’s a question we get quite often when it comes to kidney cancer.  The answer is YES. And we are black and white.  We are democrats and republicans.  We are American, German, Mexican, Brazilian, South Korean.  Kidney cancer doesn’t discriminate.  We might not agree on everything – even the color of our ribbon – but we all agree that we want a cure for kidney cancer. World Kidney Cancer Day is an effort led by the International Kidney Cancer Coalition – a fantastic organization dedicated to bringing advocacy organizations together – to remind the world that we are all united by one common factor – we all are fighting kidney cancer together.  We’re so grateful to be part of this effort and to be standing in unity today. For our part, in honor of World ...

Take our Survey and help us improve surveillance in Kidney Cancer

This year, 60,000 Americans will be diagnosed with kidney cancer.  Many of these cancers will be found incidentally – almost by accident.  Many patients are completely unprepared and don’t know what questions to ask or what kind of follow-up they should receive after their diagnosis.  While multiple guidelines exist, there isn’t a single uniform or standard plan for patients.  In an effort to improve that – we’re doing something that no one else has done.  We’re asking patients to share their experiences and to tell us what they want and what the health care system can do better!  If you’ve been diagnosed with RCC, please take a moment to fill out our survey and share with others!  By doing so, you’ll help magnify the voice of all patients. C...

Voices of Kidney Cancer – Ken’s story

Thanks Ken for sharing your story about why it's so important to have regular follow-up care after a kidney cancer diagnosis!

March is Kidney Cancer Awareness Month – Join our Facebook Campaign and tell your story!

I’ll be honest, there’s something about the word “awareness” that I’ve never really liked – I think it’s because I wish we didn’t have to be aware of kidney cancer.  And I suppose it makes sense, because our goal at KCCure is to raise money for research to eliminate kidney cancer – to end the need for an awareness month. But for now, there are too many reminders that it still exists.  Spending the day yesterday with a patient, I was reminded how little we know about rare subtypes like Translocation Xp112.  At the ASCO-GU conference in Florida last month, we saw papers presented on the need for more knowledge about Renal Medullary Carcinoma, a rare and aggressive variant of kidney cancer.  We heard from Dr. Marston Linehan about how far we’ve come in finding genetic ...

KCCure interviews Dr. Mike Atkins about the TIVO-3 trial

KCCure talks with Dr. Michael Atkins, Deputy Director of the Georgetown-Lombardi Comprehensive Cancer Center in Washington, DC about the TIVO-3 trial and what it means for kidney cancer patients.

Pearls of wisdom in an oyster cracker

I do see the pearl of wisdom even if it’s in an oyster cracker in a styrofoam cup. Today was my first and last scan for the year. A first because I’m on a different kind of treatment now which is not chemotherapy based, but immune therapy based. First scan on a new drug always has my thoughts in open waters and sinking. Oysters are heavy you know. And last, because I have no more scans for the rest of the year! If you knew how often I am scanned, (think claustrophobic tendencies AND being completely still for sometimes an hour and a half at a pop) you would also be rejoicing. Hard to swallow without hot sauce for sure and since I don’t eat oysters, the seasoned cracker kind will do just fine. I often wonder how my body can ingest all these toxins for almost 11 years living with kidney canc...

A Break From Cancer

A friend sent me a note the other day.  She said she was looking forward to the holidays, to a break from cancer.  As a caregiver to her husband, she made the decision to stop worrying and just appreciate each day for the next few weeks.  Does that sound familiar?  If you’ve experienced cancer in your life, you’ve probably said similar things. Of course, it’s a bit of a folly.  When cancer is a part of your life, you never really get a break from it.  The nagging fears and concerns lurk in the crevices of our minds.  Regardless of your situation – whether you’re stage 1 or stage 4 – the fear of recurrence, concerns about whether a treatment is working, wondering about side effects – it’s just a part of life with cancer. When KCCure first formed, we had a long brainstorming session about ou...

Reasons for Today – Flow Like Water

Holidays can be difficult for kidney cancer patients and caregivers, but there is a path to peace.

  • 1
  • 2
  • 5

Lost Password


Subscribe for updates!